Nyxoah (NASDAQ:NYXH – Get Free Report) had its price target reduced by analysts at Cantor Fitzgerald to $3.00 in a report released on Tuesday, Marketbeat.com reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price target suggests a potential upside of 250.30% from the company’s current price.
Several other equities analysts also recently weighed in on the stock. Robert W. Baird set a $2.31 price target on shares of Nyxoah in a research note on Thursday, August 6th. Wall Street Zen cut shares of Nyxoah from a “hold” rating to a “sell” rating in a research note on Sunday, August 9th. Piper Sandler reiterated an “overweight” rating and issued a $6.00 price objective (down from $7.00) on shares of Nyxoah in a report on Thursday, August 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Nyxoah in a research note on Wednesday, August 19th. Finally, Oppenheimer set a $4.00 target price on Nyxoah in a report on Thursday, August 6th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $3.66.
Read Our Latest Research Report on NYXH
Nyxoah Stock Performance
Shares of NASDAQ:NYXH opened at $0.86 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.38 and a quick ratio of 2.31. Nyxoah has a 1 year low of $0.80 and a 1 year high of $5.92. The firm has a market capitalization of $33.19 million, a PE ratio of -0.34 and a beta of 1.65. The business’s 50 day moving average price is $1.40 and its 200-day moving average price is $2.60.
Nyxoah (NASDAQ:NYXH – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.20). Nyxoah had a negative net margin of 443.16% and a negative return on equity of 178.90%. The firm had revenue of $8.76 million during the quarter, compared to analysts’ expectations of $8.64 million. As a group, equities research analysts expect that Nyxoah will post -1.44 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC purchased a new stake in Nyxoah in the second quarter valued at $169,000. IFP Advisors Inc grew its holdings in shares of Nyxoah by 35.6% during the 2nd quarter. IFP Advisors Inc now owns 118,426 shares of the company’s stock worth $200,000 after purchasing an additional 31,061 shares during the period. Finally, Readystate Asset Management LP purchased a new position in shares of Nyxoah during the 2nd quarter worth $351,000.
About Nyxoah
Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.
Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.
Featured Articles
- Five stocks we like better than Nyxoah
- AST SpaceMobile Faces Launch Risks as SpaceX Raises the Competitive Stakes
- GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
